Atomo Diagnostics (ASX:AT1) Beta: 0.9093 (As of Jun. 26, 2026)


What is Atomo Diagnostics Beta?

Atomo Diagnostics ASX:AT1 Beta is 0.9093 as of Jun. 26, 2026. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Atomo Diagnostics's Beta is 0.9093.

Atomo Diagnostics  (ASX:AT1) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Atomo Diagnostics Beta Related Terms

Atomo Diagnostics Beta Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics Beta Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial 0.00 0.00 1.48 1.91 1.35

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 1.91 1.75 1.35 0.84

ASX:AT1 vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, Atomo Diagnostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atomo Diagnostics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Beta distribution charts can be found below:

* The bar in red indicates where Atomo Diagnostics's Beta falls into.


Atomo Diagnostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.9093 mean?
Atomo Diagnostics (ASX:AT1) has a Beta of 0.9093 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Beta too high?
Atomo Diagnostics' current Beta is 0.9093.
How does Atomo Diagnostics' Beta compare to ABT and SYK?
Atomo Diagnostics' Beta of 0.9093 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Atomo Diagnostics and its competitors. Atomo Diagnostics's current Beta is 0.9093. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Beta is 0.9093. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Beta is 0.9093 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.